Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Ovarian Neoplasms 3 Fallopian Tube Neoplasms 3 Neoplasms 2 Endometrial Neoplasms 2 Triple Negative Breast Neoplasms 1 Recurrence 1 Pathologic Complete Response 1 Neoplasm Metastasis 1 Melanoma 1 Mastocytosis, Systemic 1 Lung Neoplasms 1 Hemangiosarcoma 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Arthritis, Rheumatoid 1

Interventions

pembrolizumab 156 Gemcitabine 139 Capecitabine 121 Paclitaxel 119 Fluorouracil 116 Oxaliplatin 110 Bevacizumab 104 Nivolumab 97 Leucovorin 97 Docetaxel 93 Cisplatin 90 Irinotecan 88 Carboplatin 85 Radiosurgery 83 Cyclophosphamide 71 Cetuximab 70 Magnetic Resonance Spectroscopy 68 Trastuzumab 56 Specimen Handling 56 Biopsy 56 Radiotherapy 55 Ipilimumab 52 Everolimus 48 Pemetrexed 46 Drug Therapy 45 Albumin-Bound Paclitaxel 44 130-nm albumin-bound paclitaxel 43 Doxorubicin 41 Fulvestrant 38 aldesleukin 37

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Neoplasm Metastasis × sarilumab × Clear all

NCT04333706 2026-03-10

EMPOWER

University of Southern California

Phase 1/2 Recruiting

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡